Latest Equity Funding News

Pengana Capital Group reported a strong turnaround in FY 2025 profitability, driven by a surge in private credit funds under management and successful new product launches. The firm’s strategic shift towards private markets is reshaping its revenue profile and balance sheet strength.

Marimaca Copper Corp. has released a Definitive Feasibility Study for its Marimaca Oxide Deposit in Chile, highlighting a robust 13-year mine life, low capital intensity, and strong financial returns. The study confirms a maiden ore reserve and positions the project as a competitive copper producer with advanced permitting and financing underway.

360 Capital Group has reported a significant profit increase for FY25 alongside a stable dividend and a substantial $0.40 per security special distribution, reflecting strong cash reserves and strategic growth in real estate credit.

360 Capital Group reported a remarkable 1394% increase in statutory profit for FY25, maintaining dividends while advancing its real estate credit platform and announcing a substantial special distribution.

Pacific Lime and Cement Limited has approved the Final Investment Decision for its Central Lime Project in Papua New Guinea, adopting a fully equity-funded strategy that slashes upfront capital expenditure by 42% and eliminates debt servicing costs. Construction is underway, with production expected within 18 months.

Morphic Ethical Equities Fund Limited reported a strong turnaround in FY2025 with a $5.44 million net profit and portfolio returns surpassing its benchmark, while continuing aggressive share buybacks despite withholding dividends.

NOVONIX Limited reports progress scaling its Chattanooga synthetic graphite plant, secures major funding, and benefits from U.S. tariffs on Chinese imports, while narrowing its half-year loss.

Cynata Therapeutics has entered a five-year At-the-Market Subscription Agreement with Acuity Capital, enabling access to up to $7.5 million in standby equity capital with full discretion over timing and pricing.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Arafura Rare Earths has successfully raised approximately A$80 million through a two-tranche institutional placement and launched a A$5 million share purchase plan, strengthening its cash position ahead of the Nolans project final investment decision.

Magellan Financial Group reported a solid FY25 with an 8.2% rise in assets under management and a notable surge in strategic partnership income, offsetting a dip in investment management revenue.

Magellan Financial Group reported a 5% rise in operating profit for FY25 despite a 31% drop in statutory net profit, driven by strong growth in assets under management and booming income from strategic partnerships.